Stockscreener 앱 받기
2.44
2.95%
0.07
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
ETFs Investing in Protalix Biotherapeutics, Inc. Stocks - TradingView
PLXProtalix BioTherapeutics Inc Volatility & Greeks - Finviz
Price to book forward of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
Price to sales forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Price to sales forward of Protalix Biotherapeutics, Inc. – SWB:PBDA - TradingView
Protalix BioTherapeutics, Inc. (PLX) Investigation: Bronstein, Ge - The National Law Review
Price to earnings forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Enterprise value to EBIT forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Price to earnings forward of Protalix Biotherapeutics, Inc. – FWB:PBDA - TradingView
Enterprise value to EBIT forward of Protalix Biotherapeutics, Inc. – FWB:PBDA - TradingView
Enterprise value to revenue forward of Protalix BioTherapeutics, Inc. (DE) – AMEX:PLX - TradingView
Enterprise value to EBITDA forward of Protalix Biotherapeutics, Inc. – FWB:PBDA - TradingView
Enterprise value to revenue forward of Protalix Biotherapeutics, Inc. – FWB:PBDA - TradingView
PBDA Forecast — Price Target — Prediction for 2027 - TradingView
Protalix Shareholders Approve Directors, Compensation and Incentive Plan - The Globe and Mail
Protalix BioTherapeutics, Inc. 8-K Filing Details: Company Information, Governance, and Plan Definitions (June 25, 2026) - Minichart
Protalix (NYSE: PLX) investors approve directors, pay and expanded stock plan - Stock Titan
Protalix Biotherapeutics, Inc. Actuals & Estimates (AMEX:PLX) - TradingView
Spotlight On 3 Penny Stocks With Market Caps Under $2B - simplywall.st
Protalix Biotherapeutics Inc (PLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PLX Q1 2026 Earnings: Significant Earnings Beat Driven by Key Milestone EventsConsensus Miss Rate - dars.gov.et
Protalix Biotherapeutics Inc (PLX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Protalix Biotherapeutics Inc (PLX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Protalix Biotherapeutics Inc (PLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Protalix Biotherapeutics Inc (PLX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Protalix Biotherapeutics Inc (PLX) Institutional Confidence - TradingKey
Protalix Biotherapeutics Inc (PLX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Protalix Biotherapeutics Inc (PLX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Protalix Biotherapeutics Inc (PLX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Protalix BioTherapeutics (PLX) Holds Steady at $2.08 After Minimal DeclinePercent Below MA - newsline.com
PLX Q1 2026 Earnings: EPS Rockets Past Estimates, Stock Edges LowerGuidance vs Actual - newsline.com
Protalix BioTherapeutics (PLX) Holds Near Key Support After Mild DeclineZero Lag EMA - newsline.com
Protalix BioTherapeutics (PLX) Holds Near Support After Modest DeclinePut Dominated - thelegaladvocate.com
H.C. Wainwright Maintains Protalix Biotherapeutics(PLX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Protalix BioTherapeutics (PLX) Rises 1.43% as Biotech Stock Tests Key ResistancePrice Gap Fill - The Legal Advocate
3 Penny Stocks With Market Caps Larger Than $100M To Consider - Sahm
PLX Q1 2026 Earnings: Massive EPS Surprise as Protalix BioTherapeutics Reports Strong ProfitabilityRevenue Growth Outlook - The Legal Advocate
PLX Stock Price, Quote & Chart | PROTALIX BIOTHERAPEUTICS INC (NYSEARCA:PLX) - ChartMill
Protalix Highlights Elfabrio Dosing Approvals and Growth Plans - TipRanks
Protalix BioTherapeutics Advances Rare Disease Treatments with Elfabrio® and PRX-115, Achieves Key Regulatory and Pipeline Milestones - Minichart
Protalix BioTherapeutics (PLX) posts new May 2026 corporate presentation for investors - Stock Titan
Protalix BioTherapeutics appoints Gilad Mamlok as CFO - MSN
Protalix BioTherapeutics (PLX) Q1 2026 8-K: EPS Not Disclosed, R - GuruFocus
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone - MSN
Protalix Q1 Call: Milestone-Fueled Profit, Bold Targets - The Globe and Mail
PLX: Chiesi milestone received - MSN
PLX: Chiesi Milestone Received - Yahoo Finance
Protalix BioTherapeutics 1Q Rev $33.8M >PLX - Moomoo
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2026 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results - Sahm
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlig - GuruFocus
Protalix BioTherapeutics Delivers 234% Revenue Growth in Q1 2026 - AlphaStreet
Protalix BioTherapeutics Releases Q1 2026 Financial Results - AlphaStreet
Protalix BioTherapeutics, Inc. Q1 2026 Financial Results & SEC 10-Q Filing Overview - Minichart
Protalix BioTherapeutics Reports Q1 2026 Results: $18.3M Net Income, $25M Milestone From Chiesi, and Strong Guidance for 2026 - Minichart
2.64%
자본화:
|
볼륨(24시간):